Status:
NOT_YET_RECRUITING
Sirolimus Treatment Of Patients With SLE
Lead Sponsor:
State University of New York - Upstate Medical University
Conditions:
Lupus Erythematosus, Systemic
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Phase II Double-blind, placebo-controlled, randomized treatment trial with two arms: one SIROLIMUS arm with 92 patients and one placebo arm with 92 patients. The safety and therapeutic efficacy of SIR...
Eligibility Criteria
Inclusion
- Age \> 18;
- Male or female;
- ≥ 4 ACR SLE classification criteria;
- Positive ANA at a titer of ≥ 1/80;
- Stable immunosuppressants (MMF ≤ 3 g/day, azathioprine ≤ 100 mg/day; methotrexate ≤ 15 mg/day) and/or antimalarials (hydroxychloroquine ≤ 400 mg/day) for 30 days prior to screening; stable oral corticosteroids for 2 weeks prior to screening; ≤ 20 mg/day prednisone or equivalent; stable belimumab for 90 days prior to screening;
- BILAG 2004 index (3) level A disease activity in ≥ 1 organ/system except renal or central nervous system or (ii) BILAG 2004 index level B disease activity in ≥ 2 organs/systems if no level A disease activity is present and (iii) SLEDAI ≥ 6;
- Enrollment is approved by adjudication committee.
Exclusion
- Acute SLE flare threatening vital organs;
- Pregnant or lactating;
- Female subjects who are planning to become pregnant during the study or within 3 months after last dosing or male subjects who are considering fathering a child within 3 months after last dosing;
- Abnormal laboratory test results: hemoglobin ≤ 8 g/L (8 g/dL), platelet count ≤ 70 x 109/L (70,000 cells/mm³), white blood cell count ≤ 2.0 x 109/L (2,000 cells/mm³), neutrophils: ≤ 1.5 X 109/L, proteinuria \> 3 g/day measured by 24 hour collection or spot urine protein to creatinine ratio of \>3;
- Glomerular filtration rate (GFR) \< 50 mL/min/1.73 m², any other clinically significant abnormal screening laboratory results as evaluated by the Investigator;
- Moderately serious or serious comorbidities (e.g., diabetes mellitus, congestive heart failure, chronic obstructive pulmonary disease, chronic renal insufficiency) that in investigator's opinion confers high risk for adverse events;
- Patients receiving cyclophosphamide within 3 months;
- Active chronic infections (e.g., HIV, hepatitis B virus, hepatitis C virus, mycobacteria); patients with oral steroid-dependent asthma;
- Infections requiring intravenous antibiotics within a month or oral antibiotics within two weeks of screening;
- Patients taking (unwilling or unable to stop) NAC or other antioxidants within 1 month of screening (which is considered sufficient time to revert GSH to pre-treatment levels;
- Patients receiving rituximab within 12 months or other biologic therapy within five half lives;
- Patients receiving mTOR inhibitors (rapamycin/sirolimus, everolimus);
- Patients enrolled in other interventional trials.
Key Trial Info
Start Date :
January 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2029
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT04736953
Start Date
January 1 2025
End Date
January 1 2029
Last Update
June 5 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.